Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7967461 | 1.00 | POLA1 (0.52) | POLA1SIGMAR1NPC1RAB9APOLB | |
| SCHEMBL7366006 | 0.87 | POLA1 (0.45) | POLA1SIGMAR1NPC1RAB9APOLB | |
| SCHEMBL7967459 | 0.85 | POLA1 (0.45) | POLA1SIGMAR1NPC1RAB9APOLB | |
| SCHEMBL6580889 | 0.82 | POLA1 (0.55) | POLA1SIGMAR1NPC1RAB9APOLB | |
| SCHEMBL1846867 | 0.81 | POLA1 (0.51) | POLA1SIGMAR1NPC1RAB9APOLB | |
| SCHEMBL29587519 | 0.78 | POLA1 (0.51) | POLA1SIGMAR1KDM1AMEN1KMT2A | |
| SCHEMBL4984411 | 0.78 | POLA1 (0.51) | POLA1SIGMAR1KDM1AMEN1KMT2A | |
| SCHEMBL18487244 | 0.78 | POLA1 (0.46) | POLA1SIGMAR1KDM1A | |
| SCHEMBL6580916 | 0.77 | RAB9A (0.43) | POLA1NPC1RAB9APOLBMEN1 | |
| SCHEMBL6580393 | 0.77 | KDM1A (0.49) | SIGMAR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249578-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-7241757-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2007-07-10 | — | — | US | disclosed |
| EP-1012140-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20040186090-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| US-6750243-B1 | COMPETITIVE INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASES, ESPECIALLY THROMBIN; chemical synthesis; anticoagulants; treatment of thrombosis | AstraZeneća AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1140820-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| US-6576657-B2 | Nitrogen containing heterocyclic compounds useful as anticoagulants | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-21 | — | — | US | disclosed |
| EP-1140820-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| US-6265397-B1 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1012140-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000035869-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2000-06-22 | — | — | WO | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249578-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, TFPI | POLA1 3506/4885SIGMAR1 2068/4885NPC1 3833/4885 |
| US-20040186090-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | POLA1 2357/4885SIGMAR1 1947/4885NPC1 2739/4885 |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | POLA1 2368/4885SIGMAR1 1955/4885NPC1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.